Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study.
BACKGROUND
Oral solution N-acetylcysteine (NAC) is an antidote for acetaminophen overdose, but its unpleasant taste and aroma can impede delivery even after the coadministration of antiemetic medications. Flavored effervescent NAC tablets dissolved in water might be a more palatable formulation than oral solution NAC diluted with soft drink.


OBJECTIVE
To evaluate the relative bioavailability of these 2 formulations and assess subjective preferences between them.


METHODS
Thirty healthy adult volunteers (mean [SD] = 35.2 [9.14] years) were enrolled in this open-label, randomized, single-dose, crossover study, with a 7-day washout period. Volunteers were randomized to receive 11 g effervescent test formulation or the reference product under fasting conditions, after which 19 serial blood samples were collected over 48 hours. Total plasma NAC concentrations were evaluated by LC-MS, and pharmacokinetic parameters were calculated. The 2 formulations were considered bioequivalent if the 90% CIs of log-transformed ratios of pharmacokinetic parameters were within the predetermined bioequivalence range (80%-125%) established by the US Food and Drug Administration. Within 15 minutes of dosing, subjects were also asked to rank formulation attributes on a 5-point hedonic scale, with mean group differences analyzed by Wilcoxon signed rank test. Safety-profile assessment included treatment-emergent adverse events, physical examination, chemistry, and hematology parameters.


RESULTS
The concentration-versus-time profiles were similar for the 2 formulations, with mean Cmax of 26.5 μg/mL for effervescent NAC tablets and 28.4 μg/mL for oral solution NAC. The 90% CIs for the pharmacokinetic parameters met the criteria for concluding bioequivalence, and subjects preferred effervescent NAC tablets in terms of taste (P = 0.0247), flavor (P = 0.0082), texture (P = 0.009), and overall likeability (P = 0.0012), but there was no difference for smell (P = 0.0533). All treatment-emergent adverse events were mild, with no differences between the treatment groups.


CONCLUSIONS
Data from this study of a single dose of 11 g oral NAC demonstrated that effervescent NAC tablets and oral solution NAC met the regulatory criteria for bioequivalence in fasting healthy adult subjects. Effervescent NAC tablets appear to be a more palatable alternative for treatment of acetaminophen overdose. ClinicalTrials.gov identifier: NCT02723669. (Curr Ther Res Clin Exp. 2016; 83C:1-7) © 2016 Elsevier HS Journals, Inc.
Department of Emergency Medicine, Ben Taub Hospital, Baylor College of Medicine , Houston, Texas.
Spencer C
SC
Greene
PK Noonan Pharmaceutical Consulting, LLC , Williamsburg, Virginia.
Patrick K
PK
Noonan
Spaulding Clinical Research, LLC , West Bend, Wisconsin.
Carlos
C
Sanabria
Department of Emergency Medicine, Ben Taub Hospital, Baylor College of Medicine , Houston, Texas.
W Frank
WF
Peacock
N-acetylcysteine; acetaminophen; bioavailability; effervescent tablets; pharmacokinetics
Clin Ther. 2011 Sep;33(9):1322-30
21890206
J Med Toxicol. 2009 Dec;5(4):183-90
19876849
Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):819-26
21294217
Pharm Res. 2007 Oct;24(10):1962-73
17458684
Expert Opin Pharmacother. 2011 Jan;12(1):119-30
21126198
J Med Toxicol. 2007 Dec;3(4):152-6
18072168
Clin Toxicol (Phila). 2010 Jun;48(5):424-30
20524832
Curr Pharm Biotechnol. 2012 Aug;13(10):1917-23
22352734
Clin Toxicol (Phila). 2015;53(10):962-1147
26624241
West J Emerg Med. 2013 May;14(3):218-26
23687539
N Engl J Med. 2008 Jul 17;359(3):285-92
18635433
N Engl J Med. 1988 Dec 15;319(24):1557-62
3059186
Ann Emerg Med. 2007 Sep;50(3):272-9
17210206